DND-41 In Vitro RNA Expression Analysis Assay (Northern Blooting)
CAT#: ITS-1122-YF5231
Target Cell Organism: Human
Target Cell Name: DND-41
Assay Type: Gene and Protein Expression Assays
Assay Overview
This assay is to provide DND-41-based In Vitro RNA Expression Analysis Assay (Northern Blooting) to accelerate our client's oncology projects. The assay will be customized according to the specific requirements. Please contact our scientists to discuss more details.
Target Cell Name
DND-41
Target Cell Organism
Human
Target Cell Background
DND-41 was established from the peripheral blood of 13-year-old boy with T-acute lymphoblastic leukemia (T-ALL; type III cortical) in 1977; described to carry CDKN2B (p15INK4B) and CDKN2A (p16INK4A) deletions and TP53 (p53)mutation.
Related Diseases
Acute Lymphoblastic Leukemia; ALL
Research Area
Oncology
Assay Name
In Vitro RNA Expression Analysis Assay (Northern Blooting)
Short Description
DND-41-cell based In Vitro RNA Expression Analysis Assay (Northern Blooting)
Assay Description
Northern blotting is a conventional method used to analyze RNA levels. In northern blotting, mRNA isolated from cells or tissues are quantified by gel electrophoresis and transferred to membranes and incubated with suitable probes. The probes are normally labeled with chemiluminescent substrates or radioactive isotopes. Bound RNA-probe complexes are visualized on X-ray films.
Assay Type
Gene and Protein Expression Assays
Assay Type Details
Following transcription, primary transcript RNA is converted into mature RNA by post-transcriptional modifications. Post-transcriptional modification includes three major steps namely the addition of a 5'cap, addition of a 3'polyadenylation tail and RNA splicing. Stability of RNA has been considered as very important for gene expression and proteins at the post-transcriptional level.